Develops engineered antibody drug candidates and protein technologies for cancer and autoimmune diseases, advancing its own programs and partnering with pharmaceutical and biotechnology companies.
10-K for FY2025, filed Feb 25, 2026We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients…View ↗
Our modular approach to protein engineering is a distinguishing feature of our Fc technologies. This flexibility enables us to design…View ↗
Leverage protein engineering capabilities through partnerships and collaborationsView ↗
Partners pay Xencor upfront for licenses, milestone payments when development, regulatory or sales targets are met, and royalties tied to licensed products' sales. Distinct licenses are paid when delivered; milestone and royalty payments depend on reaching milestones or partner sales.
10-K for FY2025, filed Feb 25, 2026A key part of our business strategy is to leverage our protein engineering capabilities, XmAb Fc domains and drug candidates with…View ↗
Upfront license payments are recognized as revenue upon delivery of the license, provided the license is determined to be distinct from…View ↗
Collaboration agreements may also provide for milestone payments and royalties. Milestones are generally categorized as development…View ↗
Milestone payments that were excluded from the transaction price due to the variable consideration constraint are recognized as revenue in…View ↗
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service ↗$125.6M
10-K for FY2025, filed Feb 25, 2026
$125.6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
License
Sold outright
|
0.0%
FY2022: 0.0%
|
License, FY2025
$0 Sources
|
Sold outright |
|
Milestone
Usage-based
10-K for FY2025, filed Feb 25, 2026 |
36%
FY2022: 3.3%
|
Milestone, FY2025
$45.3M Sources
|
Usage-based |
|
Royalties
Usage-based
10-K for FY2025, filed Feb 25, 2026 |
64%
FY2022: 92%
|
Royalties, FY2025
$80.3M Sources
|
Usage-based |
|
Collaboration
|
0.0%
FY2022: 4.3%
|
Collaboration, FY2025
$0 Sources
|
Pharmaceutical and biotechnology partners license Xencor's technologies and drug candidates for development and commercialization; the company also advances selected candidates itself.
10-K for FY2025, filed Feb 25, 2026We advance multiple XmAb drug candidates into early stages of clinical development and evaluate data generated from ongoing studies to…View ↗
Leverage protein engineering capabilities through partnerships and collaborationsView ↗
A key part of our business strategy is to leverage our protein engineering capabilities, XmAb Fc domains and drug candidates with…View ↗
No. It lost $91.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
$39.4MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Jul 29, 2026
Pursuant to the Settlement Agreement, the Company will receive an aggregate of $105 million in two equal payments: the first $52.5 million…View ↗
8-K, filed Mar 9, 2026
On March 4, 2026, Xencor, Inc. (the “Company”) received a notice of termination of an Amended and Restated Collaboration and License…View ↗
Fewer kinds of candidates
The older report described the pipeline as including engineered cytokines as well as bispecific antibodies. The latest report centers its development efforts on antibody candidates, including bispecific formats, and does not describe cytokine candidates as part of its pipeline.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 25, 2026
More focused oncology strategy
The older report said the company advanced bispecific antibody and cytokine candidates across its portfolio. The latest report says it has prioritized T-cell-engaging bispecific antibody programs in oncology.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 25, 2026We seek to advance multiple XmAb drug candidates into clinical development by leveraging protein engineering capabilities and our modular…View ↗
Competes with Amgen, Genmab A/S, Regeneron Pharmaceuticals, Roche Holding, Astellas, Context Therapeutics, CytomX Therapeutics, Immunocore Holdings, Janux Therapeutics, Johnson & Johnson, Rondo Therapeutics, Takeda Pharmaceutical, Third Arc Bio, Vir Biotechnology, Candid Therapeutics, Cullinan Therapeutics, Novartis, Absci, Caldera Therapeutics, and Merck &
10-K for FY2025, filed Feb 25, 2026Competition in the fields of oncology and autoimmune disease drug development is intense, with hundreds of compounds in clinical…View ↗
Loading...